- Home
- RXT vs DCTH Comparison
RXT vs DCTH Comparison
Compare RXT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- DCTH
- Stock Information
- Founded
- RXT 1998
- DCTH 1988
- Country
- RXT United States
- DCTH United States
- Employees
- RXT N/A
- DCTH N/A
- Industry
- RXT EDP Services
- DCTH Medical/Dental Instruments
- Sector
- RXT Technology
- DCTH Health Care
- Exchange
- RXT Nasdaq
- DCTH Nasdaq
- Market Cap
- RXT N/A
- DCTH 518.0M
- IPO Year
- RXT 2020
- DCTH N/A
- Fundamental
- Price
- RXT $1.44
- DCTH $14.36
- Analyst Decision
- RXT Sell
- DCTH Strong Buy
- Analyst Count
- RXT 2
- DCTH 4
- Target Price
- RXT $1.65
- DCTH $22.75
- AVG Volume (30 Days)
- RXT 701.5K
- DCTH 381.8K
- Earning Date
- RXT 05-08-2025
- DCTH 05-08-2025
- Dividend Yield
- RXT N/A
- DCTH N/A
- EPS Growth
- RXT N/A
- DCTH N/A
- EPS
- RXT N/A
- DCTH N/A
- Revenue
- RXT $2,737,100,000.00
- DCTH $53,850,000.00
- Revenue This Year
- RXT N/A
- DCTH $128.78
- Revenue Next Year
- RXT $1.73
- DCTH $54.07
- P/E Ratio
- RXT N/A
- DCTH N/A
- Revenue Growth
- RXT N/A
- DCTH 1068.87
- 52 Week Low
- RXT $1.24
- DCTH $5.30
- 52 Week High
- RXT $3.41
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- RXT 45.91
- DCTH 67.56
- Support Level
- RXT $1.37
- DCTH $11.38
- Resistance Level
- RXT $1.45
- DCTH $12.49
- Average True Range (ATR)
- RXT 0.08
- DCTH 0.57
- MACD
- RXT 0.04
- DCTH 0.22
- Stochastic Oscillator
- RXT 65.52
- DCTH 91.61
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.